This once-hot cancer-detection company's stock got cut in half after a failed trial

This once-hot cancer-detection company's stock got cut in half after a failed trial - MarketWatch# This once-hot cancer-detection company's stock got cut in half after a failed trial## Illumina's stock also took a hit, as the gene-sequencing company remains a major Grail shareholderPublished: Feb. 20, 2026 at 4:26 p.m. ETShareResize---Listen(3 min)Grail's stock was the Nasdaq's biggest loser Friday, after a key trial of its Galleri early-detection cancer test failed to meet its primary endpoint. Photo: Grai ...